knowledge -WSS

knowledge

author：hotspot 2025-09-03 05:31:39 - browse：8

Photograph of Glaxo Smith Kline headquarters in London for a story on multiple myeloma cancer treatment ahead of the 2024 ASCO conference — JUSTIN TALLIS/AFP via Getty Images

LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago after it failed a key study — is taking its next step forward.

At the annual American Society of Clinical Oncology conference in Chicago, researchers on Sunday are presenting trial data showing that the drug, called Blenrep, outperformed a standard therapeutic approach when combined with another medicine in patients with multiple myeloma. It’s the second positive study for Blenrep in myeloma in recent months, and next up could be a return to regulatory agencies to get the drug re-approved.

In an interview, Hesham Abdullah, GSK’s oncology research leader, said the company planned to submit Blenrep to regulators by the end of the year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Adele warns fans about throwing things at performers onstage

WSS

EU moves toward latest gene techniques in food production to counter climate change, shortages

Pfizer, Moderna say biotech, pharma drug development is a sprint

A bus careens into a gulch in southern Mexico, leaving 27 people dead

Suspect in Ukraine detonates explosives at a courthouse, killing himself and wounding 2 officers

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

EU moves toward latest gene techniques in food production to counter climate change, shortages

Wikipedia

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Wikipedia

Cancer drug shortages should be causing more outrage

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

Medicare details structure of new drug price negotiation program

City of Memphis, police chief oppose effort to delay lawsuit in Tyre Nichols case

DIEP, the 'gold standard' of breast reconstruction, is under threat

Ph.D. graduate surprised with gift registry: 'You deserve to be celebrated'

Novavax promises a turnaround & Lilly roils the obesity market

Pentagon will tighten controls on classified information after Discord leak

Hepatitis C has a cure — but many Americans still lack access to it

Mirador, a new biotech startup, launches with $400 million

knowledge

Pregnancy ages women, but effects reverse after delivery

2 million sign

Pregnancy ages women, but effects reverse after delivery

Supreme Court shows surprising restraint in chaotic year of crises: ANALYSIS

Readout Newsletter: Illumina, CRISPR, Regeneron

Pfizer, Moderna say biotech, pharma drug development is a sprint

focus

knowledge

hotspot

hotspot